This document provides information about a privately owned CRO founded in 1998 with approximately 30 employees headquartered in Turku, Finland and a biomarker unit located in Oulu, Finland. The CRO offers preclinical disease models, models of hormone action, analytical services, and clinical biomarker measurements to over 80 global companies, including several big pharmaceutical companies. Key benefits of partnering with this CRO include fast and flexible access to innovative disease models, high quality research expertise, adherence to study protocols and schedules, and superior cost-to-performance ratio compared to competitors.

1. Company info Privately owned full-service CRO (founded in 1998) Personnel approximately 30 FTEs Headquarters and preclinical research unit located in Turku, Finland Biomarker unit located in Oulu, Finland Sales offices in Stamford, USA and Guangzhou, China Main product lines Preclinical disease models Models of hormone action Analytical services Clinical biomarker measurements

2. Our customers In addition to companies mentioned above, we have provided our services to over 80 companies globally, including several big pharma companies Master Service Agreements with multiple pharmaceutical companies worldwide Preferred Provider for Bayer HealthCare since September 2010

3. Our customers and partners

4. Key benefits

5. Partnering advantages Fast and flexible access to innovative disease models High quality research with years of scientific expertise at your disposal Strict adherence to agreed study protocols and schedules Methods fully optimized to save your time and fixed costs Superior cost-to-performance ratio compared to competing methods Models with limited commercial availability Urodynamic measurement platform, prostatitis model, cancer metastasis models Proprietary bone cell efficacy assays From bench to patent office Results from Pharmatest’s assays have been used in patent applications both as individual claims and supportive data Pharmatest’s reports qualify as appendixes to patent application Ready for FDA and EMEA Reports from Pharmatest’s regulatory studies can be used for obtaining regulatory approval from FDA and EMEA Clinically predictive Results of Pharmatest’s assays have been reproduced in early stage clinical trials Reduce attrition in later phases of drug development

6. Service process

7. Main product lines